Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 January 2022 | Story Rulanzen Martin | Photo Supplied
Dr Mpumelelo Ncube
Dr Mpumelelo Ncube is a dynamic an academic with a clear vision of growth for the Department of Social work and its students.

A drive to be an advocate for social justice is what drove Dr Mpumelelo Ncube, the new head of the Department of Social Work, to pursue a degree and career in Social Work. “I needed to be an advocate for social justice and empowerment of the vulnerable individuals and communities,” said Dr Ncube, who took over from Prof Sandra Ferreira earlier this year. 

Dr Ncube’s academic and professional repertoire is exceptional and his deep-rooted passion for social work is definitely a bonus for the UFS Department of Social Work. He has a PhD in Social Work from the University of Johannesburg, a master’s degree in Social Development, and a Bachelor’s degree in Social Work from the University of Witwatersrand. 

Driven by the need to succeed in whatever task he sets for himself, Dr Ncube says that he strives to make the lives of those in his path better – “The positive change should, however, begin with me so that others could easily believe in my efforts.” 

Opportunity to raise a new generation

He joined academia in 2013 after working as a psychosocial services manager in the NGO sector. “My move to the UFS was in line with my career progression and the need to contribute meaningfully at a strategic level of social work education and practice,” Dr Ncube says.  

The opportunity to work in academia has in fact provided him with an excellent opportunity. “I have the opportunity to raise a new generation of social work professionals that would be passionate, ethical and professional in their practice. In that way, my impact as an educator can be felt in all corners where my students are,” Dr Ncube says. 

An academic of note 

As a senior lecturer, he also notes the tidal changes currently sweeping through academia. He says, “In the age of the fourth industrial revolution, the Social Work academic programme should be able to identify and embrace various developments that would provide the flexibility to attract postgraduate students in different places without the need for relocation. This relates to the delivery of the programme. However, apart from adapting to these changes, the Social Work programme should also foster a cultural innovation with students and enable them to embrace the technological advancements in their social work practice.”

“I have the opportunity to raise a new generation of social work professionals that would be passionate, ethical and professional in their practice.” – Dr Mpumelelo Ncube. 


Apart from being an advocate for social justice and a lecturer he also sees his position as HOD as a being a catalyst to enable others within the department to publishing more research. “Research is a key performance area for any academic, hence the mantra, ‘publish or perish’,” he says. However, he also cautions that trick of publishing research lies in “self-discipline, self-motivation and finding a research niche”.  

Social work is his passion

Social work is Dr Ncube’s passion but he also says that it is a profession, which is “seriously underutilised especially in under developing nations”. The socio-economic conditions in these countries largely drive the underutilisation. “These are nations largely plagued by poverty, unemployment, political illiteracy challenges with policy development and implementation, and moral degeneration among many challenges,” he says. In addition, it is therefore, as Dr Ncube mentions, that “the relevance of the social work profession shall be ever-present”.

  

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept